Institutional investors purchased a net $2.9 million shares of MYGN during the quarter ended June 2015 and now own 138.72% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
DANSKE BANK A/S (INVT MGMT) Bought 22.0 Thousand shares of Myriad Genetics Inc